Zobrazeno 1 - 10
of 45
pro vyhledávání: '"Michael J. Kelley"'
Autor:
Julie Lynch, Kristine E. Lynch, Christy Morrissey, Danil V. Makarov, Daniel J. Becker, Michael J. Kelley, Scott E. Sherman, Steve Y. Lee, Kyung Min Lee
Publikováno v:
JCO Precis Oncol
PURPOSEAdvances in precision oncology, including RAS testing to predict response to epidermal growth factor receptor monoclonal antibodies (EGFR mAbs) in colorectal cancer (CRC), can extend patients’ lives. We evaluated uptake and clinical use of K
Autor:
Brian Seal, Candice Yong, Trudy Buckingham, Anna Hung, Kyung Min Lee, Michael J. Kelley, Bradley J. Hintze, Yanhong Li, Shelby D. Reed, Julie Lynch, Olga V. Efimova, Pradeep J. Poonnen
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Cancer
BMC Cancer
BackgroundThe Veterans Health Administration (VHA) is the largest integrated health care system in the United States (US). Among VHA patients, the rate of use of concurrent chemoradiation therapy (CCRT) among those with unresectable, stage III non-sm
Autor:
Pradeep J. Poonnen, Bradley J. Hintze, Jenna L Armstrong, David Winski, Dilhan Weeraratne, Michael J. Kelley, Meghan Price, David Brotman, Gretchen Purcell Jackson, Vishal Vashistha, Jane L. Snowdon
Publikováno v:
JCO Oncology Practice. 17:e1012-e1020
PURPOSE: Next-generation sequencing (NGS) gene panels are frequently completed for patients with advanced non–small-cell lung cancer (NSCLC). Patients with highly actionable gene variants have improved outcomes and reduced toxicities with the use o
Autor:
Michael J. Kelley, Russell Jacobitz, Craig William Heise, Susan Rozelle, Salvador Rivas, Michael Icardi, Olivia M. Dong, Jason L. Vassy, Deepak Voora, Peruvemba Sriram, Laurence Meyer, Michael Naglich, Catherine Chanfreau-Coffinier, Jennifer G Chapman, Jill S Bates, Maria Ribeiro
Publikováno v:
Pharmacogenomics. 22:137-144
In 2019, the Veterans Affairs (VA), the largest integrated US healthcare system, started the Pharmacogenomic Testing for Veterans (PHASER) clinical program that provides multi-gene pharmacogenomic (PGx) testing for up to 250,000 veterans at approxima
Publikováno v:
JCO Precis Oncol
PURPOSE Next-generation sequencing (NGS) multigene panel testing has become widespread, including the Veterans Affairs (VA), through the VA National Precision Oncology Program (NPOP). The interpretation of genomic alterations remains a bottleneck for
Autor:
Joseph K. Salama, Christina D. Williams, Manisha Palta, Julian C. Hong, Michael J. Kelley, Matthew J. Boyer, Daphna Y. Spiegel
Publikováno v:
Journal of the National Comprehensive Cancer Network. 18:52-58
Background: Adjuvant chemotherapy (AC) after chemoradiation (CRT) and surgery for locoregionally advanced rectal cancer (LARC) is a standard of care in the United States. This study examined the role, optimal regimen, and duration of AC using data fr
Autor:
Michael J. Kelley, Thomas Brettin, Neil L. Spector, Hyunseung Yoo, Jane A. Looney, Bradley J. Hintze, Vishal Vashistha, Maulik Shukla, Christopher M Guertin, Neal Conrad, Jill E. Duffy, Pradeep J. Poonnen
Publikováno v:
JCO Precis Oncol
PURPOSE The Veterans Health Administration (VHA) is the largest cancer care provider in the United States, with the added challenge of serving more than twice the percentage of patients with cancer in rural areas than the national average. The VHA es
Autor:
Michael J. Kelley, Susanne Danus, George L. Jackson, Hayden B. Bosworth, Christina D. Williams, Dawn Provenzale, Morris Weinberger, Jennifer H. Lindquist, Leah L. Zullig, Valerie Smith
Publikováno v:
Cancer Management and Research
Purpose The growing number of colorectal cancer (CRC) survivors often have multiple chronic conditions. Comparing nonmetastatic CRC survivors and matched noncancer controls, our objectives were to determine the odds of CRC survivors being diagnosed w
Autor:
Harvey G. Moore, Julian C. Hong, Michael J. Kelley, Christina D. Williams, Daphna Y. Spiegel, Manisha Palta, Joseph K. Salama, Matthew J. Boyer
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 103:565-573
Standard therapy for locally advanced rectal cancer includes neoadjuvant chemoradiation and surgery. Complete response (CR) rates after chemoradiation can be as high as 29%, suggesting that nonoperative management (NOM) may be reasonable with appropr
Autor:
Bernadette B. Heron, Michael J. Kelley, Mark C. Geraci, Meghan C. O'Leary, A. Jasmine Bullard, Lauren A. Beste, Kourtney LaPlant, Elliott Lowy, Elise A. Stave, Christine M. Hunt, Francesca E. Cunningham, Julia M. Hammond, Bryan D. Volpp, Marsha J. Turner
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 9, Pp 1136-1146 (2018)
Hepatology Communications, Vol 2, Iss 9, Pp 1136-1146 (2018)
Hepatitis B virus (HBV) reactivation may occur with high risk immunosuppression, such as anti‐cluster of differentiation (CD)20 antibodies (Abs). Appropriate HBV prophylaxis during anti‐CD20 Ab therapy averts hepatitis, chemotherapy disruption, a